According to GlobalData’s medical device pipeline database, 39 Extracorporeal Membrane Oxygenation Devices devices are in various stages of development globally. GlobalData’s report Extracorporeal Membrane Oxygenation Devices provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Of these devices, 30 are in active development, while the remaining 11 are in an inactive stage of development. There are 24 products in the early stages of development, and the remaining six are in the late stages of development.
Patients that have developed the inability to properly oxygenate their blood, due to complications of the lung, heart or both, are candidates to receive extracorporeal membrane oxygenation (ECMO). Deoxygenated blood is drained from the venous system and oxygenated in the ECMO device before being returned to the body. ECMO Pumps, ECMO Oxygenators, Arterial Cannulae and Venous Cannulae are tracked in this segment.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Extracorporeal Membrane Oxygenation Devices pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Extracorporeal Membrane Oxygenation Devices devices. Overall, most of these Extracorporeal Membrane Oxygenation Devices pipeline devices are being developed by private entities.
Key players involved in the active development of Extracorporeal Membrane Oxygenation Devices include CVD Equipment, MedArray, MicroPort Scientific, Inspira Technologies Oxy Bhn, Suzhou LungShield Medical Tech, Suzhou Xinqing Medical Technology, Charles Stark Draper Laboratory, Thoratec, University of California San Francisco and Xenios.
For a complete picture of the developmental pipeline for Extracorporeal Membrane Oxygenation Devices devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.